Question to the Department of Health and Social Care:

To ask Her Majesty’s Government what action they have taken in the light of the recommendations of the Royal College of Ophthalmologists in 2011 that NICE and the Medicines and Healthcare products Regulatory Agency should be instructed to evaluate the effectiveness of the drug bevacizumab in the treatment of age-related macular degeneration (AMD) and produce national guidelines for the use of anti-VEGF agents in AMD.

The Department has no plans to ask the National Institute for Health and Care Excellence (NICE) to develop technology appraisal guidance on the use of bevacizumab for the treatment of age-related macular degeneration (AMD). Bevacizumab is not licensed for use in the treatment of wet AMD. Other licensed drugs are available for the treatment of AMD and have been recommended in NICE technology appraisal guidance as clinically and cost effective. The National Health Service in England is legally required to fund drugs and treatments recommended by NICE technology appraisal guidance. NICE is currently developing a clinical guideline on the diagnosis and management of AMD and currently expects to issue final guidance in August 2017.